查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1552568

多发性骨髓瘤治疗市场规模、份额、趋势分析报告：按药物、疾病、最终用途、地区、细分市场预测，2024-2030

Multiple Myeloma Therapeutics Market Size, Share & Trends Analysis Report By Drug, By Disease (Active Multiple Myeloma, Smoldering Multiple Myeloma), By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10个工作天内

价格
简介目录

多发性骨髓瘤药物市场成长与趋势：

2030年，多发性骨髓瘤药物的全球市场规模将达303亿美元，预计2024年至2030年复合年增长率为5.5%。

推动市场扩张的主要因素是不断推出更新、更有效的治疗方案及其高采用率。

随着单株抗体和组蛋白去乙酰化酶 (HDAC) 抑制剂等新药物加入目前的治疗方法，这一领域预计将获得发展动力。鑑于目前可用药物的治疗效果不佳，因此迫切需要有效的治疗策略来抵消治疗不满意并延长患者的预期寿命，这预计将推动多发性骨髓瘤改进治疗方法的研究和开发。

随着老年人口的迅速增加，这种疾病的盛行率不断上升，预计是预测期内显着推动成长的主要因素。与治疗老年患者相关的併发症正在推动对支持性治疗的需求，例如涉及输血的恢復性手术和护理点技术。

继美国之后，欧洲由于大公司的存在、更快的核准率以及有利的医疗保健政策而主导了市场。新兴经济体多发性骨髓瘤的高盛行率是推动欧洲市场成长的关键因素。

几家大公司已进入欧洲市场，包括新基公司、杨森生物技术公司、百时美施贵宝公司和诺华公司。 Celgene 公司在高性能药物Revlimid的销售中占有很大份额。该药物目前在市场上占据主导地位，占多发性骨髓瘤治疗药物市场总量的50%以上。

多发性骨髓瘤药物市场报告亮点

  • 据美国国家癌症美国称，2016 年将登记超过 30,330 例多发性骨髓瘤新病例。随着老年人口的增加，预计新病例数每年都会增加。
  • 新推出的药物可望延长多发性骨髓瘤患者的寿命，从而增加每年需要治疗的患者的累积数量。
  • 2015年，由于缺乏有效的替代选择，化疗和其他药物领域占据了全球最大的销售份额。
  • 化疗和其他药物细分为常规化疗、免疫调节剂、蛋白酶抑制剂、HDAC抑制剂和单株抗体。
  • 2015年，免疫调节剂占据了最大的市场占有率。缺乏可比较药物替代品是推动该细分市场成长的主要因素。
  • 由于 HDAC 抑制剂和单株抗体类新推出的药物的功效和安全性，预计在预测期内将显示出最快的成长。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章 多发性骨髓瘤药物市场变数、趋势与范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 多发性骨髓瘤药物市场分析工具
    • 波特的分析
    • PESTEL分析

第四章多发性骨髓瘤治疗药物市场：依药物估计与趋势分析

  • 细分仪表板
  • 多发性骨髓瘤药物市场：2023 年和 2030 年药物变化分析
  • 化疗和其他药物
  • 辐射
  • 干细胞移植和支持性治疗

第五章多发性骨髓瘤治疗药物市场：依疾病分类的估计与趋势分析

  • 细分仪表板
  • 多发性骨髓瘤药物市场：2023 年和 2030 年按疾病分类的变异分析
  • 活动性多发性骨髓瘤
  • 冒烟型多发性骨髓瘤

第六章 多发性骨髓瘤治疗药物市场：最终用途的估计和趋势分析

  • 细分仪表板
  • 多发性骨髓瘤治疗药物市场：2023 年和 2030 年最终用途的变化分析
  • 医院
  • 诊所
  • 其他的

第七章多发性骨髓瘤治疗药物市场：区域估计与趋势分析

  • 2023 年及 2030 年按地区分類的多发性骨髓瘤药物市场占有率
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国。
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Johnson &Johnson Services, Inc.
    • Novartis AG
    • Amgen Inc.
    • Sanofi
    • Bristol-Myers Squibb Company.
    • Takeda Pharmaceutical Company Limited.
    • Merck &Co.
    • AbbVie Inc.
    • GLENMARK PHARMACEUTICALS LTD.
    • DAIICHI SANKYO COMPANY, LIMITED
    • bluebird bio, Inc.
简介目录
Product Code: GVR-4-68039-913-1

Multiple Myeloma Therapeutics Market Growth & Trends:

The global multiple myeloma therapeutics market size was valued at USD 30.30 billion in 2030 and is projected to grow at a CAGR of 5.5% from 2024 to 2030. Key factors driving the market expansion include constant introduction of newer and effective therapeutic options and high adoption rates of the same.

This space is expected to gain momentum with the addition of novel drugs to the current therapeutics array with monoclonal antibodies and Histone Deacetylase (HDAC) inhibitors. Due to failed outcomes of the currently available medication, there is a high demand for effective treatment strategies to offset therapeutic dissatis faction and increase life expectancies of patients; which in turn is expected to boost the research and development of improved therapies for multiple myeloma.

Growing prevalence of the disease along with the surging elderly population is the prime factor expected to drive the growth significantly during the forecast period. Complications involved in treating geriatric patients are driving the demand for supportive treatments such as restoration procedures involving transfusion of blood components and point of care technologies.

The U.S, followed by Europe, has been dominating the market owing to the presence of major players in these regions, faster approval rates, and favorable healthcare policies. Higher prevalence of multiple myeloma in the developed economies is a pivotal determinant driving the growth of the Europe market.

The space consists of a few major players including Celgene Corporation, Janssen Biotech, Inc., Bristol-Myers Squibb Company, and Novartis AG. A large revenue share is captured by Celgene Corporation with its high-performing drug, Revlimid. The drug currently dominates the market with more than 50% share of the total multiple myeloma therapeutics market.

Multiple Myeloma Therapeutics Market Report Highlights:

  • According to the National Cancer Institute, more than 30,330 new cases of multiple myelomaare expected to register in 2016. The number of new cases is expected to grow each year with the growing geriatric population.
  • Newly introduced drugs are expected to increase the longevity of patients undergoing treatment for multiple myeloma, which yields a high cumulative number of patients requiring treatment each year.
  • In 2015, the chemotherapy and other drugs segment dominated the global space with largest revenue share owing to lack of effective alternative option.
  • Chemotherapy and other drugs segment has been sub-segmented into traditional chemotherapy, immunomodulating agents, protea some inhibitors, HDAC inhibitors, and monoclonal antibodies.
  • In 2015, immunomodulating agents drug class captured the largest market share. Absence of comparable alternatives is the prime factor driving the growth of the segment.
  • The newly introduced drugs belonging to the classes HDAC inhibitors and monoclonal antibodies are expected to show the fastest growth during the forecast period owing to the effectiveness and safety of these drugs.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Multiple Myeloma Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Multiple Myeloma Therapeutics Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Multiple Myeloma Therapeutics Market: Drug Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Multiple Myeloma Therapeutics Market: Drug Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Chemotherapy and Other Drugs
    • 4.3.1. Chemotherapy and Other Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2. Traditional Chemotherapy
      • 4.3.2.1. Traditional Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.3. Immunomodulating Agents
      • 4.3.3.1. Immunomodulating Agents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.4. Proteasome Inhibitors
      • 4.3.4.1. Proteasome Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.5. Histone Deacetylase (HDAC) Inhibitors
      • 4.3.5.1. Histone Deacetylase (HDAC) Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.6. Monoclonal Antibodies
      • 4.3.6.1. Monoclonal Antibodies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Radiation
    • 4.4.1. Radiation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Stem Cell Transplant and Supportive Treatment
    • 4.5.1. Stem Cell Transplant and Supportive Treatment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Multiple Myeloma Therapeutics Market: Disease Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Multiple Myeloma Therapeutics Market: Disease Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Active Multiple Myeloma
    • 5.3.1. Active Multiple Myeloma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Smoldering Multiple Myeloma
    • 5.4.1. Smoldering Multiple Myeloma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Multiple Myeloma Therapeutics Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Multiple Myeloma Therapeutics Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Hospitals
    • 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Clinics
    • 6.4.1. Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Other
    • 6.5.1. Other Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Multiple Myeloma Therapeutics Market: Regional Estimates & Trend Analysis

  • 7.1. Multiple Myeloma Therapeutics Market Share, By Region, 2023 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK.
      • 7.3.2.1. UK Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Johnson & Johnson Services, Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Novartis AG
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Amgen Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Sanofi
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Bristol-Myers Squibb Company.
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Takeda Pharmaceutical Company Limited.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Merck & Co.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. AbbVie Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. GLENMARK PHARMACEUTICALS LTD.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. DAIICHI SANKYO COMPANY, LIMITED
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives
    • 8.4.11. bluebird bio, Inc.
      • 8.4.11.1. Participant's Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Recent Developments/ Strategic Initiatives